Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-09-22), Mirum Pharmaceuticals's 12-1 Month Momentum % is 40.33%.
The industry rank for Mirum Pharmaceuticals's 12-1 Month Momentum % or its related term are showing as below:
FRA:08D's 12-1 Month Momentum % is ranked better than 79.11% of 1350
companies
in the Biotechnology industry
Industry Median: -20.6
vs FRA:08D: 40.33
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Mirum Pharmaceuticals 12-1 Month Momentum % Related Terms
FRA:08D vs DNTH, COGT, PTCT: 12-1 Month Momentum % Comparison
For the Biotechnology subindustry, Mirum Pharmaceuticals's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mirum Pharmaceuticals 12-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mirum Pharmaceuticals's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Mirum Pharmaceuticals's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mirum Pharmaceuticals (FRA:08D) has a 12-1 Month Momentum % of 40.33% as of Sep. 22, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Mirum Pharmaceuticals and its competitors. According to the industry distribution chart, Mirum Pharmaceuticals ranks #282 out of 1350 companies in the Biotechnology industry, placing it in the top 20.9%.
Is Mirum Pharmaceuticals' 12-1 Month Momentum % too high?
Mirum Pharmaceuticals' current 12-1 Month Momentum % is 40.33%. Based on the distribution chart, Mirum Pharmaceuticals ranks #282 out of 1350 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Mirum Pharmaceuticals has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Mirum Pharmaceuticals' 12-1 Month Momentum % compare to DNTH and COGT?
According to the Biotechnology industry distribution chart, Mirum Pharmaceuticals ranks #282 out of 1350 companies for 12-1 Month Momentum %. This places Mirum Pharmaceuticals in the top 21% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Biotechnology company?
A good 12-1 Month Momentum % depends on the Biotechnology industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Mirum Pharmaceuticals and its competitors. Mirum Pharmaceuticals's current 12-1 Month Momentum % is 40.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mirum Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Mirum Pharmaceuticals (FRA:08D) is currently considered Fairly Valued. The stock's GF Value™ is €74.28, compared to a current price of €78.04 — trading 5.1% above its estimated fair value. The current 12-1 Month Momentum % is 40.33%. Mirum Pharmaceuticals' overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Mirum Pharmaceuticals (FRA:08D), the current 12-1 Month Momentum % is 40.33% as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mirum Pharmaceuticals (FRA:08D) Overvalued in 2026?
Based on GuruFocus' analysis, Mirum Pharmaceuticals stock appears to be overvalued.
The current stock price of €78.04 is trading 5.1% above its estimated GF Value™ of €74.28.
GuruFocus considers Mirum Pharmaceuticals to be Fairly Valued.
Key valuation signals for FRA:08D:
12-1 Month Momentum %: 40.33%
GF Value™: €74.28 vs. price of €78.04 (5.1% above fair value)
No single metric tells the full story. See the FRA:08D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
52GF Score
Get the complete analysis for FRA:08D
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:08D has been successfully added to your 
